Description_x000D_ General description_x000D_ Ristomycin/ristocetin is a type III glycopeptide. It is a highly glycosylated glycopeptide, previously found in Amycolatopsis lurida._x000D_ Application_x000D_ Ristomycin monosulfate has been used:_x000D_ • to activate platelet and induce platelet aggregation_x000D_ • to study the aggregation responses of platelets from buffalo, horse, pig and sheep_x000D_ • in in-house ristocetin cofactor von Willebrand factor (VWF:RCo) assay to measure glycoprotein Ib (GpIb) binding activity_x000D_ Packaging_x000D_ 100, 250 mg in poly bottle_x000D_ Biochem/physiol Actions_x000D_ Ristocetin activates platelets. Ristocetin-induced platelet agglutination (RIPA) is decreased in patients undergoing chronic hemodialysis. Together with increased plasma glycocalicin levels (a product of enzymatic cleavage of GPIb), RIPA may contribute to diminished platelet adhesion to vascular subendothelium and increased bleeding associated with uremia. Addition of ristocetin and vWf caused specific agglutination of rGPIbα-liposomes suporting the potential use of rGPIbα-liposomes to enhance platelet function in vivo and support hemostasis in thrombocytopenic individuals._x000D_ Ristomycin possesses antibacterial activity. It may be used to diagnose von Willebrand disease and Bernard-Soulier syndrome. Ristocetin-induced platelet agglutination (RIPA) is decreased in patients undergoing chronic hemodialysis. Increased plasma glycocalicin levels (a product of enzymatic cleavage of GPIb) and decreased RIPA might reduce platelet adhesion to vascular subendothelium and improve bleeding associated with uremia in patients with chronic hemodialysis._x000D_ Other Notes_x000D_ Glycopeptide antibiotic complex